Friday, November 20, 2026

Castle Biosciences Stock Went Down By Over 13% So Far On Wednesday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Castle Biosciences Stock Went Down By Over 13% So Far On Wednesday

(VIANEWS) - Shares of Castle Biosciences (NASDAQ: CSTL) dropped by a staggering 13.44% to $17.03 at 14:24 EST on Wednesday, after two successive sessions in a row of losses. NASDAQ is rising 1.27% to $13,934.85, after two sequential sessions in a row of gains. This seems, so far, an all-around bullish trend trading session today.

Castle Biosciences's last close was $19.68, 45.48% under its 52-week high of $36.10.

About Castle Biosciences

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.71.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -18.33%.

Moving Average

Castle Biosciences's worth is way below its 50-day moving average of $19.01 and way below its 200-day moving average of $22.60.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Castle Biosciences's EBITDA is -13.64.

Volatility

Castle Biosciences's last week, last month's, and last quarter's current intraday variation average was 11.64%, 2.06%, and 5.59%.

Castle Biosciences's highest amplitude of average volatility was 14.79% (last week), 4.95% (last month), and 5.59% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Castle Biosciences's stock is considered to be oversold (<=20).

More news about Castle Biosciences (CSTL).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 12 Jul 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.